Description

Calcium Dobesilate is a vasoactive drug that presumes effects on endothelial integrity, capillary permeability and blood viscosity. It decreases capillary hyperpermeability, decreases platelet aggregation (clotting- adhesion of platelets) and reduces the serum viscosity, which improves blood circulation and blood supply to tissues and organs.

Rarely gastrointestinal disorders including nausea and diarrhea, skin reactions, fever, articular pain and in very rare cases, agranulocytosis have been reported. These reactions are generally spontaneously reversible after treatment withdrawal. In case of gastrointestinal disorders, the dosage should be reduced or the treatment temporarily withdrawn. In case of skin reactions, fever, articular pain or change in blood formula, the treatment must be stopped and the treating physician informed as this may constitute allergic reactions.

Studies in pregnant women or animals are not available. As it is not known whether calcium dobesilate crosses the placental barrier in humans, the drug should only be administered if it was estimated that the anticipated therapeutic benefit outweigh the potential risk to the fetus. Calcium dobesilate enters the maternal milk in very low quantities (0.µ4g/ml after intake of 3×500mg). As a precaution either the treatment or the breast-feeding should be stopped.

Dosage should be reduced in case of severe renal insufficiency requiring dialysis. In patient with agranulocytosis, this medication can decrease the number of white blood cells which affect the body’s ability to fight against various infections. If patients experience flu-like symptoms such as cough, sore throat, fever and others, they are advised to seek medical care as soon as possible.

The clinical signs of a possible over dosage are not known.

Vaso Protective

Store in a cool and dry place, away from light. Keep out of the reach of children.